Tag Archives: Opioid

Statement on National Academies of Sciences, Engineering, and Medicine report on framing opioid prescribing guidelines for acute pain – FDA.gov

For Immediate Release: December 19, 2019 Statement From: Statement Author Leadership Role Director – Center for Drug Evaluation and Research Janet Woodcock M.D. In August 2018, the U.S. Food and Drug Administration contracted the National Academies of Sciences, Engineering, and Medicine (NASEM) to help advance the development of evidence-based guidelines for opioid analgesic prescribing for… Read More »

Onabotulinum May Decrease Opioid Use, Reduce Severity and Frequency of Nonmigraine Headache – Neurology Advisor

In patients with chronic nonmigraine headaches who have not responded to ≥2 prophylactic therapies, onabotulinum toxin type A (BoNTA) injections may effectively reduce pain severity and frequency of headaches, a study published in Frontiers in Neurology suggests. The study was a retrospective review of 717 patients who received injections of BoNTA at a single center… Read More »

Daily on Healthcare, presented by SBEC: First federal opioid trial averted at the 11th hour

Subscribe today to the Washington Examiner magazine and get Washington Briefing: politics and policy stories that will keep you up to date with what’s going on in Washington. SUBSCRIBE NOW: Just $ 1.00 an issue! FIRST FEDERAL OPIOID TRIAL AVERTED: A major trial over the opioid crisis that was to set the stage for thousands… Read More »

Opioid latest: Judge under attack; Ohio counties demand $8B; ‘negotiating class’ wins OK

With Purdue Pharma agreeing to settle with dozens of cities and states for a record-setting $ 12 billion, more opioid settlements could be on the way. But Purdue’s agreement doesn’t mean all the defendants are willing to go to the negotiating table quietly.  On the contrary. Defendants in a Cleveland multidistrict litigation have gone so… Read More »